Difference between revisions of "Ofatumumab (Arzerra)"
m |
|||
| Line 2: | Line 2: | ||
Class/mechanism: Anti-CD20 monoclonal antibody that binds to small and large extracellular loops of the CD20 | Class/mechanism: Anti-CD20 monoclonal antibody that binds to small and large extracellular loops of the CD20 | ||
molecule which is expressed on B-cells. The Fc domain of ofatumumab has been observed in vitro to mediate | molecule which is expressed on B-cells. The Fc domain of ofatumumab has been observed in vitro to mediate | ||
| − | immune effector functions and B-cell lysis, which is hypothesized to involve complement-dependent and/or antibody-dependent cell | + | immune effector functions and B-cell lysis, which is hypothesized to involve complement-dependent cytotoxicity (CDC) and/or antibody-dependent cell mediated cytotoxicity (ADCC).<ref name="insert">[http://us.gsk.com/products/assets/us_arzerra.pdf Ofatumumab (Arzzera) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/ofatumumab.pdf Ofatumumab (Arzzera) package insert (locally hosted backup)]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref>. |
==Patient drug information== | ==Patient drug information== | ||
Revision as of 03:37, 26 February 2012
General information
Class/mechanism: Anti-CD20 monoclonal antibody that binds to small and large extracellular loops of the CD20
molecule which is expressed on B-cells. The Fc domain of ofatumumab has been observed in vitro to mediate
immune effector functions and B-cell lysis, which is hypothesized to involve complement-dependent cytotoxicity (CDC) and/or antibody-dependent cell mediated cytotoxicity (ADCC).[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].
Patient drug information
- Ofatumumab (Arzzera) patient drug information (Chemocare)[3]
- Ofatumumab (Arzzera) patient drug information (UpToDate)[4]